TuHURA Biosciences (NASDAQ:HURA) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of TuHURA Biosciences (NASDAQ:HURA) from a hold rating to a sell rating in a report released on Saturday.

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of TuHURA Biosciences in a research report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, TuHURA Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.67.

TuHURA Biosciences Stock Performance

Shares of TuHURA Biosciences stock opened at $2.57 on Friday. TuHURA Biosciences has a fifty-two week low of $1.80 and a fifty-two week high of $7.93. The company’s 50 day moving average price is $3.57 and its two-hundred day moving average price is $3.85.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

Hedge Funds Weigh In On TuHURA Biosciences

Several institutional investors have recently made changes to their positions in the stock. Accent Capital Management LLC acquired a new position in TuHURA Biosciences during the 4th quarter worth approximately $29,000. TT Capital Management LLC acquired a new position in TuHURA Biosciences during the 4th quarter worth approximately $41,000. Jefferies Financial Group Inc. acquired a new position in TuHURA Biosciences during the 4th quarter worth approximately $54,000. Bank of America Corp DE acquired a new position in shares of TuHURA Biosciences during the fourth quarter worth approximately $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of TuHURA Biosciences during the fourth quarter worth approximately $61,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.